Achilles Therapeutics plc

NasdaqCM ACHL

Achilles Therapeutics plc Market Capitalization on January 29, 2025: USD 48.27 M

Achilles Therapeutics plc Market Capitalization is USD 48.27 M on January 29, 2025, a 18.07% change year over year. Market capitalization represents total company value in stock market; higher suggests larger, more established company.

Achilles Therapeutics plc 52-week high Market Capitalization is USD 67.56 M on February 28, 2024, which is 39.96% above the current Market Capitalization.
Achilles Therapeutics plc 52-week low Market Capitalization is USD 30.20 M on September 11, 2024, which is -37.44% below the current Market Capitalization.
Achilles Therapeutics plc average Market Capitalization for the last 52 weeks is USD 41.23 M.

Key data

Date	Market Capitalization	Share Price	Price to Earnings Ratio (P/E)	Price to Sales Ratio (P/S)

NasdaqCM: ACHL

Achilles Therapeutics plc

CEO	Dr. Iraj Ali Ph.D.
IPO Date	March 31, 2021
Location	United Kingdom
Headquarters	245 Hammersmith Road
Employees	204
Sector	Health Care
Industries Pharmaceuticals Biotechnology Clinical Trials

Description

Achilles Therapeutics Plc, a clinical stage immuno-oncology biopharmaceutical company, develops precision T cell therapies to treat various solid tumors. The company's lead product candidates include CHIRON, which is in Phase I/IIa clinical trial for use in the treatment of advanced non-small cell lung cancer; and THETIS, a product candidate in Phase I/IIa clinical trial for use in the treatment of metastatic or recurrent melanoma. It is also developing products for use in the treatment of head and neck squamous cell carcinoma, renal cell carcinoma, triple negative breast cancer, and bladder cancer. The company was formerly known as Achilles TX Limited and changed its name to Achilles Therapeutics Plc in February 2021. The company was founded in 2016 and is headquartered in London, the United Kingdom.

Key trends

Past 5 years